Effectiveness and safety of sofosbuvir-based therapy against chronic hepatitis C infection after successful kidney transplantation.

Joanna Musialik Aureliusz Kolonko Katarzyna Kwiecień Aleksander Jerzy Owczarek Andrzej Więcek

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2019)

In this cohort of KTRs, the new SOF-based therapies were characterized by 100% effectiveness and good safety profiles. However, in patients co-treated with RBV, close blood Hb monitoring and early RBV dose reduction are necessary. In the majority of KTRs, antiviral therapy leads to a substantial and early decrease in CNIs levels, thus frequent measurement of CNI levels is necessary during SOF-based therapy.

Keyphrases

kidney transplantation
end stage renal disease
newly diagnosed
randomized controlled trial
hepatitis c virus
ejection fraction
chronic kidney disease
systematic review
prognostic factors
mesenchymal stem cells
cell therapy
patient reported
replacement therapy